Lilly(Eli) & Co

NYSE:LLY   3:59:57 PM EDT
243.16
-1.89 (-0.77%)
: $245.03 +1.87 (+0.77%)
Products, Strategic Combinations, Other Pre-Announcement

Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications

Published: 01/06/2022 12:00 GMT
Lilly(Eli) & Co (LLY) - Lilly and Entos Pharmaceuticals Enter Into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications.
Eli Lilly - Will Be Responsible for Selecting Plvs for Clinical Development and Commercialization.
Eli Lilly - Entos Will Receive an Initial Payment of $50 Million, Which Includes an Equity Investment by Lilly.
Eli Lilly - Entos is Also Eligible to Receive Up to $400 Million in Potential Milestone Payments, As Well As Royalties.
Eli Lilly - No Change to Lilly's 2021 Or 2022 Non-GAAP Earnings per Share Guidance As a Result of Transaction.
Eli Lilly - Has Acquired Exclusive Rights to Entos Pharmaceuticals' Fusogenix Nucleic Acid Delivery Technology.